Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma

作者：Ono Takeharu^*; Azuma Koichi; Kawahara Akihiko; Sasada Tetsuro; Hattori Satoshi; Sato Fumihiko; Shin Buichiro; Chitose Shun Ich; Akiba Jun; Hirohito Umeno

来源：Oncotarget, 2017, 8(54): 92699-92714.

DOI：10.18632/oncotarget.21564

• PD-L1
• immunohistochemistry
• hypopharyngeal squamous cell carcinoma
• neoadjuvant chemotherapy
• CD8+TILs

Limited information is available regarding the immune-related prognostic factors of patients with advanced hypopharyngeal squamous cell carcinoma (HPSCC). The expression of programmed cell death-ligand 1 (PD-L1) in tumor cells contributes to a mechanism that allows cancer cells to escape immune surveillance. We investigated whether PD-L1 or human leukocyte antigen (HLA) class I expression in tumor cells and the tumor-infiltrating lymphocyte (TIL) density were associated with the tumor response to neoadjuvant chemotherapy (NAC) and survival in patients with advanced HPSCC. We retrospectively reviewed 83 consecutive patients with stage III or IV HPSCC who received NAC. We evaluated PD-L1 and HLA class I expression and TIL density using immunohistochemistry. Univariate and multivariate analyses demonstrated that CD8(+) TIL density was an independent and significant predictive factor for the response to NAC, progression-free survival (PFS) and overall survival (OS), whereas PD-L1 or HLA class I expression did not significantly correlate. The subgroup analysis revealed that a higher CD8(+) TIL density without detectable PDL-1 expression tended to be associated with longer patient survival. These results suggest that PD-L1 expression levels combined with CD8(+) TIL density may serve as a predictive biomarker for patients with stage III or IV HPSCC receiving NAC.

• 出版日期2017-11-3